DE60238035D1 - Cystinderivate und inhibitoren zur aktivierung von entzündungsfaktoren - Google Patents
Cystinderivate und inhibitoren zur aktivierung von entzündungsfaktorenInfo
- Publication number
- DE60238035D1 DE60238035D1 DE60238035T DE60238035T DE60238035D1 DE 60238035 D1 DE60238035 D1 DE 60238035D1 DE 60238035 T DE60238035 T DE 60238035T DE 60238035 T DE60238035 T DE 60238035T DE 60238035 D1 DE60238035 D1 DE 60238035D1
- Authority
- DE
- Germany
- Prior art keywords
- inhibitors
- activation
- cystine derivatives
- ignition factors
- ignition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Polymers & Plastics (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001027367A JP2002226457A (ja) | 2001-02-02 | 2001-02-02 | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
PCT/JP2002/000222 WO2002062751A1 (fr) | 2001-02-02 | 2002-01-16 | Nouveaux derives de cystine et inhibiteurs de l'activation des facteurs inflammatoires |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60238035D1 true DE60238035D1 (de) | 2010-12-02 |
Family
ID=18892029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60238035T Expired - Lifetime DE60238035D1 (de) | 2001-02-02 | 2002-01-16 | Cystinderivate und inhibitoren zur aktivierung von entzündungsfaktoren |
Country Status (6)
Country | Link |
---|---|
US (1) | US6914075B2 (de) |
EP (1) | EP1364943B1 (de) |
JP (1) | JP2002226457A (de) |
KR (1) | KR100839008B1 (de) |
DE (1) | DE60238035D1 (de) |
WO (1) | WO2002062751A1 (de) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
WO2002072040A1 (fr) * | 2001-03-13 | 2002-09-19 | Ajinomoto Co., Inc. | Produits cosmetiques ou preparations a usage externe pour la peau |
JP4151782B2 (ja) * | 2002-10-31 | 2008-09-17 | 株式会社ミルボン | 整髪料 |
EA010108B1 (ru) * | 2003-10-15 | 2008-06-30 | Пробиодруг Аг | Применение эффекторов глутаминил- и глутаматциклаз |
US20070078093A1 (en) * | 2003-10-16 | 2007-04-05 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating cancer |
JPWO2005094814A1 (ja) * | 2004-03-31 | 2008-02-14 | 興和株式会社 | 外用剤 |
DE102004020060B3 (de) * | 2004-04-20 | 2005-06-02 | Coty B.V. | Kosmetisches Verfahren zur Behandlung der Haut mit Sonnenprodukten und Sonnenprodukt-Kombination |
EP1799242A4 (de) * | 2004-09-16 | 2009-11-11 | Univ California | Peptide vom typ g und andere wirkstoffe zur linderung von atherosklerose und anderen erkrankungen |
EP1886681A3 (de) * | 2004-10-07 | 2008-11-19 | Sulfidris S.r.l. | 5-(p-Hydroxyphenyl)-3H-1,2-Dithiol-3-Thion-Valproatester |
CA2595067A1 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
US20060140927A1 (en) | 2004-12-23 | 2006-06-29 | Nonomura Arthur M | Cytochrome P450 enzyme complexes and methods of treatment using the same |
US20090234011A1 (en) * | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
EP2368561B1 (de) * | 2005-04-29 | 2013-12-04 | The Regents of The University of California | Peptide und Peptidmimetika zur Behandlung von Pathologien, die durch eine Entzündungsreaktion gekennzeichnet sind |
WO2006136871A1 (en) * | 2005-06-21 | 2006-12-28 | Codex V S.R.L. | Use of pollen extracts to treat infections, neoplasms and to balance the immune response |
CA2645833C (en) | 2006-03-15 | 2014-12-30 | Suntory Limited | Compositions containing riboflavin and sesamin-class compounds |
US20070224154A1 (en) * | 2006-03-21 | 2007-09-27 | Access Business Group International, Llc | Methods of reducing skin irritation |
US9233112B2 (en) | 2006-04-13 | 2016-01-12 | Lupin Limited | Pharmaceutical compositions of cefixime |
US8367085B2 (en) | 2006-06-12 | 2013-02-05 | Lvmh Recherche | Cosmetic composition with anti-free radical activity |
US8372455B2 (en) | 2006-06-12 | 2013-02-12 | Lvmh Recherche | Cosmetic composition with anti-free radical activity |
FR2902002B1 (fr) * | 2006-06-12 | 2010-08-27 | Lvmh Rech | Composition cosmetique anti-radicaux libres |
EP2081570A2 (de) * | 2006-10-24 | 2009-07-29 | David W. Krempin | Antiresorptive und knochenaufbauende diätnahrungszusätze und verfahren zu ihrer verwendung |
US20100172994A1 (en) * | 2006-11-22 | 2010-07-08 | University Of Florida Research Foundation, Inc. | Nanoparticles for Protection of Cells from Oxidative Stress |
EP1932524A1 (de) * | 2006-12-13 | 2008-06-18 | Ludwig-Maximilians-Universität München | Pharmazeutische Präparate zur Behandlung von Entzündungserkrankungen |
JP5046756B2 (ja) * | 2007-06-27 | 2012-10-10 | 富士フイルム株式会社 | 分散組成物及びスキンケア用化粧料並びに分散組成物の製造方法 |
CA2680751C (en) * | 2007-03-15 | 2016-01-26 | Suntory Holdings Limited | Use of dioxabicyclo[3.3.0]octane derivatives as anti-fatigue agents |
US7829709B1 (en) | 2007-08-10 | 2010-11-09 | Marquette University | Cysteine prodrugs to treat schizophrenia and drug addiction |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
DK2682400T5 (da) | 2007-08-28 | 2017-11-27 | Uab Research Foundation | Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse |
EP2252596B1 (de) | 2008-02-07 | 2016-12-28 | Marquette University | Cystein- und cystinprodrugs zur behandlung von schizophrenie und zur verminderung von drogensucht |
JP2011513510A (ja) * | 2008-02-21 | 2011-04-28 | エス.シー. ジョンソン アンド サン、インコーポレイテッド | 高い自己接着性を有し残留による利益を提供する洗浄組成物 |
US8980813B2 (en) | 2008-02-21 | 2015-03-17 | S. C. Johnson & Son, Inc. | Cleaning composition having high self-adhesion on a vertical hard surface and providing residual benefits |
US8993502B2 (en) * | 2008-02-21 | 2015-03-31 | S. C. Johnson & Son, Inc. | Cleaning composition having high self-adhesion to a vertical hard surface and providing residual benefits |
US8143206B2 (en) * | 2008-02-21 | 2012-03-27 | S.C. Johnson & Son, Inc. | Cleaning composition having high self-adhesion and providing residual benefits |
US9410111B2 (en) | 2008-02-21 | 2016-08-09 | S.C. Johnson & Son, Inc. | Cleaning composition that provides residual benefits |
US9481854B2 (en) | 2008-02-21 | 2016-11-01 | S. C. Johnson & Son, Inc. | Cleaning composition that provides residual benefits |
EP2265594A2 (de) * | 2008-04-16 | 2010-12-29 | Marquette University | Cystein- und cystin-bioisoester zur behandlung von schizophrenie und zur milderung von drogenentzugserscheinungen |
CN103251631A (zh) * | 2008-05-13 | 2013-08-21 | 根梅迪卡治疗公司 | 用于治疗代谢性病症的水杨酸盐(酯)缀合物 |
US20100069288A1 (en) * | 2008-09-12 | 2010-03-18 | Wulf Droge | Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival |
ITMI20081947A1 (it) * | 2008-11-05 | 2010-05-06 | Vitrupharma Srl | Nuovo uso di una combinazione di resveratrolo o suo analogo ed un metabolita della cisteina |
ITMI20090110A1 (it) * | 2009-01-30 | 2010-07-31 | Vitrupharma Srl | Nuovo uso di una combinazione di resveratrolo o suo uso analogo e la cisteina o suo derivato |
WO2010086736A2 (en) * | 2009-01-30 | 2010-08-05 | Vitrupharma S.R.L. | Novel use of the combination of resveratrol with cysteine and derivatives thereof |
EP2408443A1 (de) * | 2009-03-16 | 2012-01-25 | Genmedica Therapeutics SL | Entzündungshemmende und antioxidative konjugate zur behandlung von stoffwechselerkrankungen |
US20100239552A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Combination Therapies for Treating Metabolic Disorders |
US7897184B1 (en) * | 2009-08-13 | 2011-03-01 | Access Business Group International Llc | Topical composition with skin lightening effect |
US8192745B2 (en) * | 2010-01-11 | 2012-06-05 | Madere Shawn P | Nutritional supplement to improve supplementary target protein fraction (TPF) delivery, intracellular absorption and utilization |
US8808757B2 (en) * | 2010-02-26 | 2014-08-19 | Jaxsen's Llc | Herbal ointment for musculoskeletal and joint-related conditions |
WO2011116034A1 (en) * | 2010-03-17 | 2011-09-22 | Lutran Industries, Inc. | Human medicinal treatment and product typically based on salt of peroxymonosulfuric acid, and associated product fabrication |
US10383894B2 (en) * | 2010-03-17 | 2019-08-20 | Lutran Industries, Inc. | Human medicinal treatment using salt of peroxymonosulfuric acid |
US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
KR20150064091A (ko) * | 2012-10-04 | 2015-06-10 | 엑스바이오테크, 인크. | 정신의학적 병태의 치료법 |
US9023399B2 (en) * | 2012-11-16 | 2015-05-05 | NU Technology, LLC | Water-soluble anti-inflammatory cream with natural ingredients base |
AU2015298263B2 (en) | 2014-07-31 | 2020-05-14 | Anji Pharmaceuticals, Inc. | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
JP6838743B2 (ja) | 2015-06-08 | 2021-03-03 | 公立大学法人大阪 | 非ペプチド性gapdh凝集阻害剤 |
US10196591B2 (en) | 2015-07-10 | 2019-02-05 | S. C. Johnson & Sons, Inc. | Gel cleaning composition |
US10358625B2 (en) | 2015-07-17 | 2019-07-23 | S. C. Johnson & Son, Inc. | Non-corrosive cleaning composition |
US10000728B2 (en) | 2015-07-17 | 2018-06-19 | S. C. Johnson & Son, Inc. | Cleaning composition with propellant |
WO2017034793A1 (en) | 2015-08-27 | 2017-03-02 | S. C. Johnson & Son, Inc. | Cleaning gel with glycine betaine amide |
US10723978B2 (en) | 2015-08-27 | 2020-07-28 | S. C. Johnson & Son, Inc. | Cleaning gel with glycine betaine ester and nonionic surfactant mixture |
WO2017099932A1 (en) | 2015-12-07 | 2017-06-15 | S.C. Johnson & Son, Inc. | Acidic hard surface cleaner with glycine betaine amide |
WO2017099933A1 (en) | 2015-12-07 | 2017-06-15 | S.C. Johnson & Son, Inc. | Acidic hard surface cleaner with glycine betaine ester |
CN108451970B (zh) * | 2018-04-03 | 2021-03-02 | 徐州工程学院 | 一种提取银杏叶多糖的方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2480079A (en) * | 1945-08-08 | 1949-08-23 | Upjohn Co | Ring cleavage of 4-carboxythiazolidine compounds |
KR20010075000A (ko) | 1998-10-09 | 2001-08-09 | 에가시라 구니오 | 시스테인 유도체 |
CA2348946A1 (en) * | 1998-11-06 | 2000-05-18 | Roche Diagnostics Gmbh | Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
-
2001
- 2001-02-02 JP JP2001027367A patent/JP2002226457A/ja not_active Withdrawn
-
2002
- 2002-01-16 DE DE60238035T patent/DE60238035D1/de not_active Expired - Lifetime
- 2002-01-16 KR KR1020037010095A patent/KR100839008B1/ko not_active IP Right Cessation
- 2002-01-16 WO PCT/JP2002/000222 patent/WO2002062751A1/ja active Application Filing
- 2002-01-16 EP EP02715745A patent/EP1364943B1/de not_active Expired - Lifetime
-
2003
- 2003-08-04 US US10/632,959 patent/US6914075B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2002226457A (ja) | 2002-08-14 |
EP1364943A1 (de) | 2003-11-26 |
US20040059110A1 (en) | 2004-03-25 |
KR20030075172A (ko) | 2003-09-22 |
KR100839008B1 (ko) | 2008-06-19 |
EP1364943A4 (de) | 2006-01-25 |
US6914075B2 (en) | 2005-07-05 |
EP1364943B1 (de) | 2010-10-20 |
WO2002062751A1 (fr) | 2002-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60238035D1 (de) | Cystinderivate und inhibitoren zur aktivierung von entzündungsfaktoren | |
DE60206344D1 (de) | Baueinheit von Leuchten und Zubehör | |
EE200300459A (et) | Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena | |
AR028253A1 (es) | Inhibidores de la glucogeno fosforilasa | |
DE60301350D1 (de) | Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile | |
DE60217715D1 (de) | Vorrichtung zur ablation von gewebe | |
DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE60122196D1 (de) | Synergistische antioxidans-kombination von delta tocols und polyphenolen | |
DE60220661D1 (de) | Transdermales pflaster zur verabreichung von fentanyl | |
DE60219292D1 (de) | Pyrazolderivate zur behandlung von hiv | |
EE200100659A (et) | Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks | |
EE05481B1 (et) | Kinasoliini derivaadid kasvajate raviks | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
DE60207627D1 (de) | Überzug und Überzugszusammensetzung | |
DE60238576D1 (de) | Zusammensetzung zur Herstellung von Elektroden und Elektroden | |
ATE451921T1 (de) | Phenylindole zur behandlung von hiv | |
DE60132732D1 (de) | Primerzusammensetzung und Verbindungsverfahren | |
DE60210265D1 (de) | Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren | |
DE60322451D1 (de) | 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung | |
DE50010774D1 (de) | Anlage zur bearbeitung von wafern | |
DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE60214542D1 (de) | Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks | |
DE60113533D1 (de) | Derivate von beta-aminosäurenitrilen | |
DE50013866D1 (de) | Anlage zur bearbeitung von wafern | |
DE60106968D1 (de) | Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren |